Medicaid coverage practices for approved gene and cell therapies: Existing barriers and proposed policy solutions
Molecular Therapy - Methods & Clinical Development · 2023-06 · 29 · 513-521
DOI: 10.1016/j.omtm.2023.05.015 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Therapy - Methods & Clinical Development, 2023-06. Verfasst von Jeremy Allen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Spark Therapeutics, Inc., Philadelphia, PA 19104, USA. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
The current Medicaid system is ill equipped to handle the anticipated approvals of new gene and cell therapy products. These advanced therapies tend to be single-dose, potentially durable options for a variety of indications spanning oncology, rare disease, and more. The up-front cost of these therapies contrasts with chronic care treatment, which may incur cost over the life of a patient. The cost of these innovative treatments, along with the anticipated larger patient pools, can limit patient access as Medicaid programs operate on limited or fixed budgets. Given the value of these therapies for diseases that may have large Medicaid populations, the system will need to grapple with the existing barriers to access to ensure equitable patient care. This review focuses on one such barrier, discrepancies between product indications and state Medicaid and Medicaid Managed Care Organization coverage policies, and it proposes federal policy solutions to this barrier to better accommodate the exponential growth of the gene and cell therapy pipeline.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Spark Therapeutics, Inc., Philadelphia, PA 19104, USA.
- Sarepta Therapeutics, Inc., Cambridge, MA 02142, USA.
- REGENXBIO Inc., Rockville, MD 20850, USA.
- Emerging Therapy Solutions, Bloomington, MN 55425, USA.
- Center for Cell and Gene Therapy, Texas Children's Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
- Bristol Myer Squibb Company, Washington, DC 20004, USA.
Zitieren
APA
Allen, J., Berry, D., Cook, F., Hume, A., Rouce, R., Srirangam, A., Wellman, J., & McCombs, C. (2023). Medicaid coverage practices for approved gene and cell therapies: Existing barriers and proposed policy solutions. Molecular Therapy - Methods & Clinical Development, 29, 513-521. https://doi.org/10.1016/j.omtm.2023.05.015
Vancouver
Allen J, Berry D, Cook F, Hume A, Rouce R, Srirangam A, et al. Medicaid coverage practices for approved gene and cell therapies: Existing barriers and proposed policy solutions. Molecular Therapy - Methods & Clinical Development. 2023;29:513-521. doi:10.1016/j.omtm.2023.05.015
BibTeX
@article{Allen2023,
author = {Allen, Jeremy and Berry, Diane and Cook, Francesca and Hume, Ashley and Rouce, Rayne and Srirangam, Anirudh and Wellman, Jennifer and McCombs, Caitlin},
title = {Medicaid coverage practices for approved gene and cell therapies: Existing barriers and proposed policy solutions},
journal = {Molecular Therapy - Methods & Clinical Development},
year = {2023},
volume = {29},
pages = {513--521},
doi = {10.1016/j.omtm.2023.05.015}
}
EUVIMED